Antifungal Drugs Market Report and Forecast 2023-2031

The global antifungal drugs market value was USD 14.8 billion in 2022, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2023-2031 to achieve a value of USD 20.6 billion by 2031.

Antifungal Drugs Market: Introduction

Antifungal drugs are medications used to treat fungal infections, which can affect various parts of the body, including the skin, nails, mouth, lungs, and other organs. These infections can be caused by a wide range of fungi, including Candida, Aspergillus, and Cryptococcus species. Antifungal drugs work by inhibiting the growth of fungi or killing them outright. They are available in various forms, such as oral tablets, creams, ointments, and intravenous injections.

Antifungal Drugs Market Scenario

The global market for antifungal drugs has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of fungal infections, the growing geriatric population, and advancements in antifungal drug development.

North America: The largest market for antifungal drugs, driven by factors such as the advanced healthcare infrastructure, high prevalence of fungal infections, and significant investments in antifungal drug research.

Europe: The second-largest market, with increasing demand for antifungal drugs due to a growing aging population, a supportive regulatory framework, and an expanding pharmaceutical sector.

Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of fungal infections, and growing investments in healthcare infrastructure and pharmaceutical research.

Antifungal Drugs Market Segmentation

Market Breakup by Drug Class

Azoles

• Voriconazole
• Posaconazole
• Isavuconazole
• Others

Echinocandins

• Caspofungin
• Micafungin
• Others

Polyenes

• Amphotericin B
• Others

Allylamines

• Terbinafine
• Others
• Others

Market Breakup by Indication

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Mucormysosis
• Others

Market Breakup by Dosage Form

• Oral
• Cream and Ointments
• Powders
• Injection
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Key Trends in the Antifungal Drugs Market

Increasing prevalence of fungal infections: The rising incidence of fungal infections, particularly among immunocompromised individuals, such as patients undergoing chemotherapy or organ transplant recipients, has led to a growing demand for antifungal drugs, driving market growth.

Growing geriatric population: The aging population is more susceptible to fungal infections due to their weakened immune systems, further fuelling the demand for antifungal medications.

Advancements in antifungal drug development: The development of new antifungal drugs with improved efficacy and safety profiles has contributed to market growth. Additionally, the emergence of drug resistance among certain fungal species has spurred research into new antifungal therapies.

Competitor Landscape of the Antifungal Drugs Market
The report gives an in-depth analysis of the key players involved in the antifungal drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Abbott Laboratories
• GlaxoSmithKline PLC
• Novartis AG
• Pfizer Inc
• BAYER AG
• SANOFI
• MERCK & CO., INC
• ASTELLAS PHARMA, INC
• SCYNEXIS INC.